Research across Hepatitis B
Related studies from across the Hepatitis B family.
Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients
Adding peg-interferon to standard treatment helps some hepatitis B patients
This meta-analysis of 581 patients with chronic hepatitis B evaluates peg-interferon add-on to nucleoside analogue therapy. The analysis fou…
Adding peg-interferon to standard nucleoside therapy can help some patients with chronic hepatitis B achieve a key milestone in their treatm…
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
HBsAg prevalence 9.98% in Cameroon, higher-risk groups 12.70%
New data reveals high rates of Hepatitis B in Cameroon
This meta-analysis of 100 studies estimates HBsAg prevalence at 9.98% in Cameroon, with lower-risk populations at 8.94% and higher-risk at 1…
Nearly 10 percent of people in Cameroon test positive for Hepatitis B, with higher rates found in certain high-risk groups.
Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B
Immune Markers May Predict Outcomes After Hepatitis B Treatment
This mini review synthesizes immune correlates of outcome after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Bene…
New research identifies specific immune markers that may help predict how patients respond when stopping nucleoside analogue medications for…
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease
Liver disease and hepatitis B may fuel each other
This systematic review examines the interplay between viral infection and metabolic factors in patients with chronic hepatitis B and metabol…
Hepatitis B and fatty liver disease may worsen each other, raising liver cancer risk. New review explains the link.
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development
Elevated M2BPGi Levels Linked to Higher Risk of Liver Cancer
This systematic review and meta-analysis of 12,161 participants found that elevated serum M2BPGi is significantly associated with an increas…
A large review of over 12,000 patients found that high levels of a specific protein may signal an increased risk for liver cancer.
Dolutegravir and lamivudine achieved 78% HIV-1 RNA suppression in patients with isolated reactive anti-HBc
Trial shows dolutegravir and lamivudine are safe for patients with HIV
This pooled analysis of Phase 3/3b trials evaluated dolutegravir/lamivudine (DTG/3TC) in adults with HIV-1 and isolated reactive hepatitis B…
A review of multiple trials shows that a common two-drug regimen effectively manages HIV while remaining safe for those with hepatitis B ant…
JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors
Specific Immune Inhibitors Show Varying Risks for Hepatitis B Reactivation
This meta-analysis of 29 studies evaluated the risk of hepatitis B virus reactivation (HBVr) in patients receiving various immunomodulators.…
New analysis shows that certain immune inhibitors like JAK inhibitors may carry a higher risk of hepatitis B reactivation than other drug cl…
HBeAg seroclearance in HBeAg-positive chronic hepatitis B correlates with disease remission and reduced hepatocellular carcinoma risk
Clearing HBeAg helps manage chronic hepatitis B and liver risk
This systematic review examines the clinical significance and optimization strategies of HBeAg seroclearance in patients with HBeAg-positive…
Achieving HBeAg seroclearance in patients with chronic hepatitis B can lead to disease remission and a lower risk of developing liver cancer…
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations
HLA genes shape HIV and hepatitis vaccine responses and drug reactions
This narrative review examines HLA polymorphisms in HIV, hepatitis C, and hepatitis B. The clearest preventive paradigm is HLA-B*57:01-guide…
A review finds that HLA genes strongly influence how people respond to HIV and hepatitis vaccines and how they react to certain medications.